Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Cash & Equivalents (2017 - 2025)

Selectis Health's Cash & Equivalents history spans 13 years, with the latest figure at $417125.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 50.24% year-over-year to $417125.0; the TTM value through Sep 2025 reached $417125.0, down 50.24%, while the annual FY2024 figure was $680332.0, 54.17% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $417125.0 at Selectis Health, down from $559983.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.9 million in Q4 2021 and bottomed at $417125.0 in Q3 2025.
  • The 5-year median for Cash & Equivalents is $927808.0 (2022), against an average of $1.6 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 780.46% in 2021 before it crashed 73.56% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $3.9 million in 2021, then crashed by 38.66% to $2.4 million in 2022, then crashed by 38.57% to $1.5 million in 2023, then tumbled by 54.17% to $680332.0 in 2024, then tumbled by 38.69% to $417125.0 in 2025.
  • Per Business Quant, the three most recent readings for GBCS's Cash & Equivalents are $417125.0 (Q3 2025), $559983.0 (Q2 2025), and $736919.0 (Q1 2025).